We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Independent minded

8 January 2010 By Alexander Smith

The eye care firm’s independent directors aren’t powerless to push Novartis to raise its offer to buy out minorities. The Swiss drugs group could replace them with stooges who might back its current bid. But this would have reputational costs. The directors can exploit that.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)